NCT02614898 - Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 4, 2015

Primary Completion Date

October 5, 2017

Study Completion Date

October 5, 2017

Conditions

Atypical Hemolytic Uremic Syndrome

Interventions

OTHER

Eculizumab

This study was an observational study. Therefore, the study drug was not provided as part of this study, and the dosing regimen was based solely at the discretion of the treating physician.

Trial Locations (24)

2145

Clinical Trial Site, Westmead

2170

Clinical Trial Site, Liverpool

2747

Clinical Trial Site, Kingswood

3050

Clinical Trial Site, Parkville

3052

Clinical Trial Site, Parkville

3084

Clinical Trial Site, Heidelberg

3168

Clinical Trial Site, Clayton

4102

Clinical Trial Site, Woolloongabba

5000

Clinical Trial Site, Adelaide

6008

Clinical Trial Site, Perth

6109

Clinical Trial Site, Nedlands

20007

Clinical Trial Site, Washington D.C.

23538

Clinical Trial Site, Lübeck

24105

Clinical Trial Site, Kiel

28203

Clinical Trial Site, Charlotte

30322

Clinical Trial Site, Atlanta

30625

Clinical Trial Site, Hannover

Clinical Trial Site, Hanover

43210

Clinical Trial Site, Columbus

60611

Clinical Trial Site, Chicago

77030

Clinical Trial Site, Houston

02115

Clinical Trial Site, Boston

07601

Clinical Trial Site, Hackensack

NW3 2PF

Clinical Trial Site, London